DunnhumbyUSA promotes executives
CINCINNATI — DunnhumbyUSA has named two executives to the role of SVP.
Dave Palm, who will become SVP operations, is responsible for driving the daily operations of dunnhumbyUSA, as well as the company’s growth strategies, resource management and facilities. Palm previously served as VP organization engagement at DunnhumbyUSA, a role in which he oversaw the company’s resources and capabilities in helping Dunnhumby’s clients to align the totality of their organizations around their customer-centric vision.
DunnhumbyUSA said that Rex Davis, SVP and head of India operations, oversees the company’s general operations for the Gurgaon, India, office and the analyst and technology teams responsible for storing and interpreting customer data and insights for clients around the world. Prior to his current role, Davis served as VP insights and led Dunnhumby’s custom insights solution group.
Winn-Dixie adopts Bi-Lo’s price optimization tool
CINCINNATI — KSS Retail, a Dunnhumby company, on Thursday announced that Bi-Lo, the Jacksonville, Fla.-based parent company of Bi-Lo and Winn-Dixie grocery stores, has extended its business relationship with KSS Retail.
What began as an assignment with the Bi-Lo banner now has grown to include price modeling and optimization services for the Winn-Dixie banner.
“The KSS price optimization tool has strengthened BI-LO’s value message with consumers by focusing their pricing efforts on the right items and the right locations,” stated Bruce Steadman, group VP local merchandising and owned brands. “The combined company will leverage this success across both banners, further enhancing the customer experience and ensuring that customers are provided with the best possible prices on all the products they regularly purchase with us.”
Lundbeck adds Omnicare to limited distribution network for Huntington’s drug
ORLANDO, Fla. — The specialty pharmacy operated by Omnicare Specialty Care Group has been added to the limited distribution network for a drug used to treat a hereditary degenerative disorder.
Omnicare said Friday that Lundbeck had added Advanced Care Scripts to its network for Xenaziner (tetrabenazine). The drug is used to treat involuntary movements known as chorea associated with Huntington’s disease. Chroea affects about 90% of people with Huntington’s and is considered a hallmark of the disease, according to studies.
"As the only approved treatment for chorea, Xenazine represents an important advancement for patients with Huntington’s disease," Omnicare SVP David Hileman said. "We are please to be part of this innovative drug’s limited distribution network and the exclusive partner of product in the long-term care channel."
Huntington’s affects about 1-in-10,000 Americans, and about 200,000 people are at risk of developing it, according to the Huntington’s Disease Society of America, which says every child of a parent with the disease has a 50% chance of inheriting the gene that causes it.
ACS will dispense the drug using blister packs, which Hileman said would improve safety and adherence while reducing the risk of dosing errors and allow better coordination of combined therapies. "We offer this simplified solution to help patients with Huntington’s disease manage their prescription regimens," Hileman said.